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ABSTRACT
Background. Standard treatment for localized soft tissue
sarcoma (STS) is resection plus adjuvant radiotherapy
(RTx). In approximately 10% of cases, resection would
cause severe loss of function or even require amputation
because of the extent of disease. Isolated limb perfusion
(ILP) with tumor necrosis factor alpha (TNF-a) and mel-
phalan can achieve regression of the tumor, facilitating
limb-saving resection. RTx improves local control but may
lead to increased morbidity.
Methods. In our database of over 500 ILPs, 122 patients
with unifocal STS were treated by ILP followed by limb-
sparing surgery. All included patients were candidates for
amputation.
Results. Surgery resulted in 69 R0 resections (57%), and
in 53 specimens (43%) resection margins contained
microscopic evidence of tumor (R1). Histopathological
examination revealed[50% ILP-induced tumor necrosis in
59 cases (48%). RTx was administered in 73 patients
(60%). Local recurrence rate was 21% after median follow-
up of 31 months (2–182 months). Recurrence was signiﬁ-
cantly less in patients with[50% ILP-induced necrosis
versus B50% necrosis (7% vs. 33%, P = 0.001). A similar
signiﬁcant correlation was observed for R0 versus R1
resections (15% vs. 28%, P = 0.04). In 36 patients with R0
resection and[50% necrosis, of whom 21 were spared
RTx, no recurrences were observed during follow-up.
Conclusions. In patients with locally advanced primary
STS, treated with ILP followed by R0 resection, and
with[50% ILP-induced necrosis in the resected specimen,
RTx is of no further beneﬁt.
Soft tissue sarcomas (STSs) are a heterogeneous group
of rare malignancies. In the USA, 8,680 new cases of STS
are diagnosed annually, of which approximately 60% are
located in the extremities.
1 STSs are associated with early
metastasis and a high disease-speciﬁc mortality rate of
approximately 50%. Moreover, STS of the extremity is
often large at time of presentation, making local resection
and tumor control difﬁcult.
1 Local control may require
extensive surgery, resulting in loss of limb function or
amputation in 10% of cases. Amputation, however, is not
associated with prolonged survival, because survival is
determined by the occurrence of systemic disease.
2,3 Since
amputation has no beneﬁcial effect on survival, growing
interest in limb-salvaging techniques has arisen. Isolated
limb perfusion (ILP) is a technique that results in perfusion
of a tumor with high concentrations of tumor necrosis
factor alpha (TNF-a) and melphalan under hyperthermic
conditions. Following introduction of the technique in the
early 1990s, Eggermont et al.
4 reported encouraging results
in a large European multicenter study. Subsequent studies
showed high local response and limb salvage rates and
acceptable local and systemic toxicity.
5
Currently,useofILPfollowed byresectionandRTx isan
established strategy for limb salvage in Europe. Long-term
morbidity has been described after ILP.
6 A contributing
factor to morbidity is adjuvant RTx.
6 However, whether
adjuvant RTx is necessary for all patients treated with ILP
remainsunclear.Theaimofthisstudyistoidentifyaspeciﬁc
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DOI 10.1245/s10434-010-1400-xgroup of patients in whom adjuvant RTx was of no further
beneﬁt for tumor control. All patients in our hospital
undergoing ILP for unifocal STS of the extremity followed
by local resection were identiﬁed. Subsequently, we deter-
mined whether patients with STS of the extremity may be
spared adjuvant RTx under speciﬁc circumstances.
PATIENTS AND METHODS
Patients
From August 1991 to March 2009, 511 ILPs were per-
formed in our hospital. These 511 cases comprised 168
melanomas, 306 STS, and 37 miscellaneous malignancies
(Fig. 1).
ILP was the treatment strategy in 74 cases of multiple
STS, while 232 patients were treated for unifocal disease.
In this retrospective study we evaluated all 122 consecutive
ILPs (in 120 patients) for unifocal STS followed by limb-
sparing surgical resection. The minimal tumor–node–
metastasis (TNM) stage was IB, while the vast majority of
STS was staged as IIB. Liposarcoma was the most common
treated type of STS in our study, of which 3 were well
differentiated, 2 were dedifferentiated, 7 were pleomor-
phic, and 16 were of myxoid subtype. Patient characteris-
tics are summarized in Table 1.
Perfusion
The technique of ILP with TNF-a and melphalan has
been described previously.
4,5 Brieﬂy, the procedure is
performed with patients under general anesthesia. After
heparinization, a targeted blood circuit is isolated by
clamping and cannulation of the major artery and vein and
connection to an oxygenated extracorporeal circuit. A
tourniquet compresses collateral vessels and prevents
leakage. Using a precordial scintillation probe to detect
technetium-labeled albumen, leakage is monitored for the
length of the procedure. Patients underwent ILP via axil-
lary (n = 9), brachial (n = 19), iliac (n = 54), femoral
(n = 24) or popliteal (n = 16) approach.
511 ILP
306 Sarcoma
168 Melanoma
37
Miscellaneous
74 Multifocal
232 Unifocal
132 Resection
81 No resection
19 Amputation
122 ILP 
10 Missing data
included
FIG. 1 Inclusion ﬂow chart
TABLE 1 Patient and tumor characteristics
N%
Gender
Female 55 45.1
Male 67 54.9
Age
B50 years 56 45.9
[50 years 66 54.1
Size
\5 cm 20 16.4
5–10 cm 34 27.9
[10 cm 68 55.7
Trojani grade
1 11 9.0
2 31 25.4
3 73 59.8
Missing 7 5.7
Site
Upper arm 8 6.6
Elbow 5 4.1
Lower arm 10 8.2
Wrist or hand 5 4.1
Upper leg 46 37.7
Knee 20 16.4
Lower leg 22 18.0
Ankle or feet 6 4.9
Histology
Liposarcoma 28 23.0
Synovial sarcoma 24 19.7
HGPS NOS 16 13.1
Leiomyosarcoma 12 9.8
Other (16 types) 43 34.4
Primary/recurrent
Primary 102 83.6
Recurrent 20 16.4
Adjuvant RTx
No 49 40.2
Yes 73 59.8
HGPS NOS high-grade pleomorphic sarcoma not otherwise speciﬁed
322 J. P. Deroose et al.A dose of 1–3 mg (arm) or 1–4 mg (leg) recombinant
TNF-a (Boehringer Ingelheim GmbH, Ingelheim/Rhein,
Germany) was injected as a bolus once the temperature of
the limb reached 38C. Subsequently, 13 mg/l (arm) or
10 mg/l (leg) melphalan (L-PAM; Alkeran, Burroughs
Wellcome Ltd., London, UK) was administered 30 min
after the limb temperature reached 38–39.5C. The median
dose of TNF-a administered was 4.0 mg (mean 3.2 mg,
range 1–4 mg), while the median dose of melphalan was
75 mg (mean 79.8 mg, range 18–160 mg). Several studies
reported successful use of reduced doses of TNF-a in ILP
for STS with comparable local recurrence rates and no
systemic toxicity.
7,8 Thereafter, perfusion was executed
with 1 mg TNF-a in the arm and 2 mg in the leg. Conse-
quently, since 2005 the median dose of TNF-a has been
2.0 mg (mean 2.09 mg, range 1–3 mg). After 90 min of
perfusion, the limb was washed out with 1 l (arm) to 4 l
(Iliac perfusion) physiological saline solution and 6%
dextran (Macrodex Pharmacia, Uppsala, Sweden). Patients
were observed in intensive care unit (ICU) for one night.
Median length of hospital stay was 8 days (mean 11 days,
range 2–136 days).
Clinical response was deﬁned using clinical ﬁndings and
magnetic resonance imaging (MRI). Complete response
(CR) was deﬁned as complete remission of tumor tissue,
while partial response (PR) was deﬁned as 51–99%
remission. No change (NC) was deﬁned as 0–50% remis-
sion. Clinical evidence of new lesions or growth of the
tumor was deﬁned as progressive disease (PD).
Local Control
Whenever the response of the tumor to ILP appeared to
facilitate local resection without major limb function loss,
local resection was attempted. Local resection was per-
formed at median of 84 days (mean 91 days, range
14–260 days) after ILP. Margine status of the resection
was deﬁned using the criteria according to Pisters et al.
9 In
each surgical specimen the peripheral margins were inked.
A microscopically positive (R1) margin was deﬁned as
unequivocal tumor extension to the inked margin on per-
manent section. Cases in which tumor was close to but did
not reach the inked margin were considered to have
microscopically negative margins (R0). The percentage of
the tumor that was necrotic due to ILP was estimated by the
pathologist by macroscopic inspection and microscopic
conﬁrmation. Two categories were deﬁned: 51–99%
necrosis of the tumor and 0–50% necrosis of the tumor.
Radiotherapy
Adjuvant RTx was administered to 73 (60%) patients,
while 49 (40%) patients did not receive RTx. Like all other
decisions concerning STS, decisions on the subject of
adjuvant RTx were made in a multidisciplinary board
containing a surgical oncologist, a medical oncologist, a
radiation oncologist, a pathologist, and a radiologist.
Before 1998, there was little evidence that adjuvant RTx
was beneﬁcial after local resection of STS. Since Olieman
et al.
10 reported improved outcome after adjuvant RTx in
1998, our center has administered signiﬁcantly more RTx
(P = 0.04). Reasons for refraining from administering
adjuvant RTx after 1998 are summarized in Table 2.
RESULTS
Clinical Response
Clinical response after ILP was complete in ﬁve cases
(4%). PR was obtained in 80 patients (66%), NC in 35
patients (29%), and PD in 1 patient (1%). Clinical response
was not assessed in one patient (1%) for unknown reason.
Local Control
Results are summarized in Table 3. Local resection of
the STS resulted in R0 resection in 69 patients (57%),
while 53 (43%) patients had R1/R2 resection. The overall
local recurrence rate was 21% (25 patients) after median
follow-up of 31 months (mean 48 months, range
2–182 months); 5-year recurrence-free survival (RFS) was
75% (±5% standard error, SE). If recurrence occurred,
median time to recurrence was 15 months (mean
27 months, range 3–170 months). After R0 resection,
5-year RFS was 80%, while patients with R1 resection had
5-year RFS of 72%. This difference reached signiﬁcance
(P = 0.04, Fig. 2).The local recurrence rate was 15% in
the R0 group (10 patients), while the R1 group had a local
recurrence rate of 28% (15 patients). In 13 cases (11%),
amputation, after limb-saving resection, was deemed nec-
essary during follow-up. Median time between limb-
sparing resection and amputation was 29 months (mean
25 months, range 2–60 months). Consequently, the limb
salvage rate was 89%.
TABLE 2 Reasons for no RTx after 1998
N %
Systemic disease 8 40
Joint/hand/foot 3 15
Age/comorbidity 2 10
Refused by patient 1 5
Reason not speciﬁed 6 30
Total 49 100.0
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mens revealed[50% ILP-induced tumor necrosis in 59
cases (48%). In 63 (52%) cases the response to ILP was
50% or less. Patients with[50% necrosis in specimen after
resection had 5-year RFS of 92%, while patients
with B50% necrosis had 5-year RFS of 61%. As can be
seen in Fig. 3, this difference was signiﬁcant (P = 0.001).
In the group with[50% necrosis of the tumor, the local
recurrence rate was 7% (4 cases), compared with 33% (21
cases) in the group with B50% tumor necrosis. None of the
patients were treated with adjuvant systemic chemotherapy
or any other treatment modality in the time interval
between ILP and resection. Combining these results we
could deﬁne a group of 43 patients (35%) with R0 resection
and[50% tumor necrosis, with a single case of local
recurrence. This concerned a patient who was treated for
local recurrence. This female, aged 44 years, had no signs
of residual vital tumor in the resected specimen. Since the
tumor had been small and difﬁcult to locate preoperatively,
the completeness of the resection was deemed doubtful.
Therefore, RTx was proposed, but refused by the patient. In
retrospect, we believe that the tumor was not resected
during surgery.
None of the patients with R0 resection and[50%
necrosis who were treated for primary STS (n = 36)
developed local recurrence. Patients with R0 resection but
less than 50% necrosis of tumor (n = 26) showed recur-
rence in nine cases (35%).
The local recurrence rate for patients treated with
adjuvant RTx was 23%, while patients not treated with
RTx had local recurrence in eight cases (16%). Whether
patients with R0 resection had RTx was not based on main
tumor characteristics (Table 4).
DISCUSSION
Our results suggest that patients with primary and uni-
focal STS of the extremity, in whom R0 resection is
achieved after successful ILP (induction of[50% necro-
sis), may not beneﬁt from adjuvant RTx. In these patients,
the recurrence rate was 0%. Patients treated for recurrence
TABLE 3 Results for all STS
R Histology (%) N Recurrence Recurrence rate (%)
No RTx R0 B50 7 1 14.3
R0 [50 28 1
a 3.6
R1 B50 8 4 50.0
R1 [50 6 2 33.3
Total 49 8 16.3
RTx R0 B50 19 8 42.1
R0 [50 15 0 0.0
R1 B50 29 8 27.6
R1 [50 10 1 10.0
Total 73 17 23.3
Total R0 69 10 14.5
R1 53 15 28.3
B50 63 21 33.3
[50 59 4 6.8
Total 122 25 20.5
a One patient with local recurrence of a secondary diagnosed STS
0.2
0.4
0.6
0.8
1.0
Log rank:  p = 0.04
Nr at Risk
R0
R1
Total
0
66
53
122
60
Months
Recurrence-free 
survival
12 24 36 48
20
11
31
57
34
91
39
22
61
34
17
51
27
14
41
R0
R1
FIG. 2 Local recurrence versus R0/R1
0.2
0.4
0.6
0.8
1.0
Log rank:  p = 0.001
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> 50%
 50%
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0
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Recurrence-free 
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45
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> 50%
≤
≤
 50%
FIG. 3 Local recurrence versus histopathological response
324 J. P. Deroose et al.of STS (n = 7), who had R0 resection and[50% tumor
necrosis, showed local recurrence in one case.
The overall local recurrence rate in our series was 21%,
which is in accordance with several other studies describ-
ing ILP as a limb-saving strategy for STS (11–34%), while
reported recurrence rates for primarily resectable STS
range from 10 to 27%.
5,7,10–18
ACRrateof4%seemslowcomparedwiththerateof28%
in the multicenter trial published by Eggermont et al. or in
comparison with the latest studies of Bonvalot at al. (30%;
n = 100), Grabellus et al. (15%; n = 47), and Pennachioli
et al. (41%; n = 88).
7,14–16 The discordance is due to
selection bias, since we only included patients with limb-
sparingsurgeryafterILP.Thevastmajoritiesofpatientswith
MRI-proven CR were not considered for resection and had
clinical follow-up for 10 years. Another bias was the
exclusion of multifocal tumors in general (Lev–Chelouche,
CR = 38, n = 53) or Stewart–Treves lymphangiosarcoma
(Lans et al., CR = 56%; n = 16), which are known to
respond well to ILP.
19,20 With the introduction of the use of
TNF-a in ILP there was a substantial improvement in treat-
ment for nonresectable extremity STS.
4,5,12,21,22 Nowadays
ILPwithdelayedresectionisanestablishedstrategyforlimb
salvage in Europe. Median time span between resection and
ILP was 84 days, which was within the range of previous
reports (42–117 days).
22,23 Completeness of resection is an
important prognostic factor for local recurrence.
14,17,18,24–26
After R0 or R1 resection in patients with over 50% tumor
necrosis,alocalrecurrencerateofonly7%wasobserved.Of
patients with B50% necrosis in resection specimen, 33%
had recurrence. This highly signiﬁcant difference suggests
that the degree of ILP-mediated tumor necrosis might be an
even stronger prognostic factor for local recurrence and
supports the ﬁndings of Grabellus et al.
14 that improved
margin status is achieved after ILP. In patients with R1
resection with[50% necrosis, 19% local recurrence was
observed.Thisisanotableimprovementincomparisonwith
thelargeanalysis(n = 1,041)ofPistersetal.whoreporteda
local recurrence rate of 40% for R1 resection of extremity
STS without ILP.
18 Considering the larger proportion of
largetumors([10 cm;25vs.56%)inourseries,thisresultis
more remarkable.
It could be argued that determining the degree of
necrosis may not necessarily reﬂect a therapy effect but
may be inherent tumor necrosis. Furthermore, macroscopic
evaluation is a subjective and therefore imprecise factor.
Considering the fact that tumor necrosis in untreated STS is
an independent unfavorable prognostic factor, it may be
assumed that the necrosis observed in ILP-treated sarcomas
is indeed therapy related and prognostically relevant.
Second, considering the broad categories deﬁned for tumor
necrosis in grading systems (0,\50, and[50%) it is
highly unlikely that the degree of necrosis in single cases
falls near the cutoff point. Furthermore, in our experience
the pattern of necrosis in ILP-treated sarcomas, consisting
of large conﬂuent areas of necrosis, is different from the
patch pattern of necrosis seen as spontaneous necrosis in
untreated sarcomas. Finally, the MRIs that were performed
before ILP showed central necrosis in only 7 (12%) of 59
cases with[50% ILP-induced necrosis.
The value of adjuvant RTx after ILP and resection is
still unclear. The beneﬁcial effect of irradiation in limb-
saving surgery for STS was ﬁrst demonstrated by Rosen-
berg et al.
2 Despite reporting a signiﬁcant decrease in STS
local recurrence after irradiation therapy, Yang et al.
27
concluded that, in selected patients with low risk for
recurrence, irradiation should not be considered because of
important lifetime risk for complications. Other studies
claimed that adjuvant RTx in all cases had a signiﬁcant
positive inﬂuence in obtaining local control.
10,23
Complications of RTx should not be underestimated.
Hoven-Gonderie et al.
28 reported that two-thirds of all
patients experienced serious late toxic problems after
combined treatment for STS. Major problems with wound
healing and continuous wound infections (8–14%) are
described in literature.
29,30 Vascular damage (4–14%) is a
common long-term complication of RTx.
6,30,31 Kalman
et al.
32 described four cases of long-term vascular side-
effects in the axillary artery after mastectomy with adju-
vant RTx, 10–27 years after treatment. RTx may cause
neuropathy, especially when a boost is given.
28,33
TABLE 4 R0 resection ± RTx
RTx
No Yes
Size
\5c m 7 5
5–10 cm 11 8
[10 cm 17 21
Trojani grade
15 1
21 4 9
31 6 2 2
Missing 0 2
Histology
Liposarcoma 9 7
Synovial sarcoma 4 8
HGPS NOS 7 3
Leiomyosarcoma 4 2
Other (16 types) 11 14
Primary/recurrent
Primary 26 29
Recurrent 9 5
HGPS NOS high-grade pleomorphic sarcoma not otherwise speciﬁed
RTx for STS after ILP and Surgical Resection 325Although radiation is effective in improving local con-
trol,several studiessuggestthat,after margin-free resection,
a subset of patients do not beneﬁt from RTx.
14,34,35 In a
prospective study, Pisters et al.
9 reported that patients with
T1, R0-resected STS have acceptable long-term local con-
trol and may be spared the short- and long-term toxicity
of RTx.
In our series, patients were not randomized for adjuvant
RTx, so the conclusions based on our ﬁndings have to be
read with caution. Furthermore, with 36 patients in
18 years, the deﬁned group that can be spared RTx is rel-
atively small. Further studies should be performed to
conﬁrm these ﬁndings. Nevertheless, our results suggest
that patients with R0 resection combined with[50% ILP-
induced necrosis may be spared adjuvant RTx. The beneﬁt
of adjuvant RTx after ILP followed by limb-sparing sur-
gery for this subset of patients seems limited. The added
morbidity, the lack of survival beneﬁt, and the limited
effect on local recurrence should be discussed with these
patients.
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